Using marginal structural measurement-error models to estimate the long-term effect of antiretroviral therapy on incident AIDS or death

American Journal of Epidemiology

Volumn 171, Issue 1, 2010, Pages 113-122

  Cole, Stephen R ^a   Jacobson, Lisa P ^b   Tien, Phyllis C ^c,d   Kingsley, Lawrence ^e   Chmiel, Joan S ^f   Anastos, Kathryn ^g  

^a IL   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e UNIVERSITY OF PITTSBURGH   (United States)

^f NORTHWESTERN UNIVERSITY   (United States)

^g ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Acquired immunodeficiency syndrome; Bias (epidemiology); Cohort studies; Confounding factors (epidemiology); Epidemiologic measurements; HIV; Pharmacoepidemiology; Selection bias

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; COHORT ANALYSIS; DISEASE INCIDENCE; DISEASE TREATMENT; EPIDEMIOLOGY; ERROR ANALYSIS; HUMAN IMMUNODEFICIENCY VIRUS; MORTALITY; REGRESSION ANALYSIS;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGED; ARTICLE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; TREATMENT RESPONSE; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIAS (EPIDEMIOLOGY); COHORT STUDIES; CONFOUNDING FACTORS (EPIDEMIOLOGY); FEMALE; HIV INFECTIONS; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MODELS, STATISTICAL; MULTICENTER STUDIES AS TOPIC; NORTH CAROLINA; PHARMACOEPIDEMIOLOGY; PROPORTIONAL HAZARDS MODELS; REGRESSION ANALYSIS; STATISTICS AS TOPIC; UNITED STATES;

UNITED STATES;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 72949091835     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwp329     Document Type: Article

References (57)

1. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med. 1997;337(11):725-733.
2. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy [see comments]. N Engl J Med. 1997;337(11): 734-739.
3. Cameron DW, Heath-Chiozzi M, Danner S, et al. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group. Lancet. 1998;351(9102):543-549.
4. Miettinen OS. The need for randomization in the study of intended effects. Stat Med. 1983;2(2):267-271.
5. Greenland S, Robins JM. Identifiability, exchangeability, and epidemiological confounding. Int J Epidemiol. 1986;15(3): 413-419.
6. Robins J. The control of confounding by intermediate variables. Stat Med. 1989;8(6):679-701.
7. Robins JM, Greenland S. Identifiability and exchangeability for direct and indirect effects. Epidemiology. 1992;3(2):143-155.
8. Cole SR, Hernán MA. Fallibility in estimating direct effects (with discussion). Int J Epidemiol. 2002;31(1):163-165.
9. Hernán MA, Hernández-D́iaz S, Robins JM. A structural approach to selection bias. Epidemiology. 2004;15(5): 615-625.
10. Cole SR, Hernán MA, Robins JM, et al. Effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome or death using marginal structural models. Am J Epidemiol. 2003;158(7):687-694.
11. Sterne JA, Hernán MA, Ledergerber B, et al. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet. 2005; 366(9483):378-384.
12. Robins JM, Hernán MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology. 2000;11(5):550-560.
13. Hernán MA, Brumback B, Robins JM. Marginal structural models to estimate the joint causal effect of non-randomized treatments. J Am Stat Assoc. 2001;96(454):440-448.
14. Stefanski LA, Carroll RJ. Covariate measurement error in logistic regression. Ann Stat. 1985;13:1335-1351.
15. Rosner B, Willett WC, Spiegelman D. Correction of logistic regression relative risk estimates and confidence intervals for systematic within-person measurement error. Stat Med. 1989;8(9):1051-1069; discussion 1071-1073.
16. Spiegelman D, McDermott A, Rosner B. Regression calibration method for correcting measurement-error bias in nutritional epidemiology. Am J Clin Nutr. 1997;65(4 suppl): 1179S-1186S.
17. Spiegelman D, Rosner B, Logan R. Estimation and inference for logistic regression with covariate misclassification and measurement error, in main study/validation study designs. J Am Stat Assoc. 2000;95:51-61.
18. Kaslow RA, Ostrow DG, Detels R, et al. The Multicenter AIDS Cohort Study: rationale, organization, and selected characteristics of the participants. Am J Epidemiol. 1987; 126(2):310-318.
19. Barkan SE, Melnick SL, Preston-Martin S, et al. The Women's Interagency HIV Study. WIHS Collaborative Study Group. Epidemiology. 1998;9(2):117-125.
20. Lamarca R, Alonso J, Gómez G, et al. Left-truncated data with age as time scale: an alternative for survival analysis in the elderly population. J Gerontol A Biol Sci Med Sci. 1998;53(5): M337-M343.
21. Wang MC, Brookmeyer R, Jewell NP. Statistical models for prevalent cohort data. Biometrics. 1993;49(1):1-11
22. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep. 1992;41(RR-17): 1-19.
23. Hessol NA, Schwarcz S, Ameli N, et al. Accuracy of self-reports of acquired immunodeficiency syndrome and acquired immunodeficiency syndrome-related conditions in women. Am J Epidemiol. 2001;153(11):1128-1133.
24. Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the Use of Antiretroviral Agents in HIV-1-infected Adults and Adolescents. (http://aidsinfo.nih.gov/ Guidelines/). (Accessed November 3, 2008).
25. Mellors JW, Muñoz A, Giorgi JV, et al. Plasma viral load and CD4 lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med. 1997;126(12):946-954.
26. Abbott RD. Logistic regression in survival analysis. Am J Epidemiol. 1985;121(3):465-471.
27. Cole SR, Hernán MA, Anastos K, et al. Determining the effect of highly active antiretroviral therapy on changes in human immunodeficiency virus type 1 RNA viral load using a marginal structural left-censored mean model. Am J Epidemiol. 2007;166(2):219-227.
28. Hernán MA, Cole SR. Invited commentary: Causal diagrams and measurement bias. Am J Epidemiol. 2009;170(8):959-962.
29. Cole SR, Hernán MA, Margolick JB, et al. Marginal structural models for estimating the effect of highly active antiretroviral therapy initiation on CD4 cell count. Am J Epidemiol. 2005; 162(5):471-478.
30. Cole SR, Hernán MA. Constructing inverse probability weights for marginal structural models. Am J Epidemiol. 2008;168(6):656-664.
31. White HA. A heteroskedasticity-consistent covariance matrix estimator and a direct test of heteroskedasticity. Econometrica. 1980;48:817-838.
32. Mark SD, Robins JM. A method for the analysis of randomized trials with compliance information: an application to the Multiple Risk Factor Intervention Trial. Control Clin Trials. 1993;14(2):79-97.
33. Cole SR, Chu H. Effect of acyclovir on herpetic ocular recurrence using a structural nested model. Contemp Clin Trials. 2005;26(3):300-310.
34. Greenland S, Lanes S, Jara M. Estimating effects from randomized trials with discontinuations: the need for intent-to-treat design and G-estimation. Clin Trials. 2008;5(1): 5-13.
35. Detels R, Muñoz A, McFarlane G, et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. JAMA. 1998;280(17): 1497-1503.
36. Greenland S. An introduction to instrumental variables for epidemiologists. Int J Epidemiol. 2000;29(4):722-729.
37. Cain LE, Cole SR, Chmiel JS, et al. Effect of highly active antiretroviral therapy on multiple AIDS-defining illnesses among male HIV seroconverters. Am J Epidemiol. 2006;163 (4):310-315.
38. Cain LE, Cole SR, Greenland S, et al. Effect of highly active antiretroviral therapy on incident AIDS using calendar period as an instrumental variable. Am J Epidemiol. 2009;169(9): 1124-1132.
39. Neugebauer R, Van der Laan M. Nonparametric causal effects based on marginal structural models. J Stat Plan Inference. 2007;137:419-434.
40. Ahdieh L, Gange SJ, Greenblatt R, et al. Selection by indication of potent antiretroviral therapy use in a large cohort of women infected with human immunodeficiency virus. Am J Epidemiol. 2000;152(10):923-933.
41. Cole SR, Frangakis CE. The consistency statement in causal inference: a definition or an assumption? Epidemiology. 2009; 20(1):3-5.
42. Hernán MA. Invited commentary: Hypothetical interventions to define causal effects-afterthought or prerequisite? Am J Epidemiol. 2005;162(7):618-620; discussion 621-622.
43. Hernán MA, Taubman SL. Does obesity shorten life? The importance of well-defined interventions to answer causal questions. Int J Obes (Lond). 2008;32(suppl 3): S8-S14.
44. Hernán MA, Brumback B, Robins JM. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology. 2000;11(5): 561-570.
45. Lau B, Gange SJ, Moore RD. Interval and clinical cohort studies: epidemiological issues. AIDS Res Hum Retroviruses. 2007;23(6):769-776.
46. Lau B, Gange SJ, Kirk GD, et al. Evaluation of human immunodeficiency virus biomarkers: inferences from interval and clinical cohort studies. Epidemiology. 2009;20(5):664-672.
47. Robins JM. General methodological considerations. J Econometrics. 2003;112:89-106.
48. Goetghebeur E, Vansteelandt S. Structural mean models for compliance analysis in randomized clinical trials and the impact of errors on measures of exposure. Stat Methods Med Res. 2005;14(4):397-415.
49. Cole SR, Chu H, Greenland S. Multiple-imputation for measurement-error correction. Int J Epidemiol. 2006;35(4): 1074-1081.
50. Greenland S. Bayesian perspectives for epidemiological research: I. Foundations and basic methods. Int J Epidemiol. 2006;35(3):765-775.
51. Greenland S. Bayesian perspectives for epidemiological research. II. Regression analysis. Int J Epidemiol. 2007;36(1): 195-202.
52. Greenland S. Multiple-bias modelling for analysis of observational data. J R Stat Soc (A). 2005;168:267-306.
53. Cain LE. Bridging the Gap Between Observational and Randomized Evidence: HAART and AIDS [dissertation]. Baltimore, MD: Johns Hopkins Bloomberg School of Public Health; 2008.
54. Brouwer ES, Napravnik S, Corbett AH, et al. A validation study of self reported antiretroviral use within a clinical cohort of HIV positive patients. Pharmacoepidemiol Drug Saf. 2008; 17(S1):S3.
55. Carroll RJ, Stefanski LA. Approximate quasi-likelihood estimation in models with surrogate predictors. J Am Stat Assoc. 1990;85:652-663.
56. Pearl J. Causal diagrams for empirical research. Biometrika. 1995;82:669-710.
57. Pearl J. Causality. New York, NY: Cambridge; 2000.